📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Loading analysis...
Religare Subsidiary Care Health Appoints Ajay Kumar Shah as MD & CEO for 5-Year Term
Religare Enterprises has announced the appointment of Ajay Kumar Shah as the Managing Director & CEO of its material subsidiary, Care Health Insurance Limited (CHIL), effective April 26, 2026. Mr. Shah, who has been with CHIL for 14 years, succeeds the outgoing leadership as part of an internal succession plan. The appointment has already received necessary approval from the IRDAI for a five-year tenure. Given his history as Chief Business Officer where he oversaw a 30x growth in Gross Written Premium, the transition is expected to be stable.
Key Highlights
Ajay Kumar Shah appointed as MD & CEO of Care Health Insurance for a 5-year term starting April 26, 2026
IRDAI has already granted approval for the appointment, ensuring regulatory compliance
Mr. Shah has over 30 years of experience and has spent 14 years at CHIL in various leadership roles
Under his leadership as Chief Business Officer, CHIL's Gross Written Premium (GWP) grew more than 30-fold over 10 years
The appointment follows an internal succession plan, suggesting continuity in business strategy
💼 Action for Investors
Investors should take confidence in the internal succession and the appointee's strong track record of scaling the insurance business. No immediate action is required, but monitor the subsidiary's growth trajectory under the new leadership.
Loading analysis...
Religare Subsidiary Care Health Appoints Ajay Kumar Shah as MD & CEO for 5 Years
Religare Enterprises has announced the appointment of Mr. Ajay Kumar Shah as the Managing Director & CEO of its material subsidiary, Care Health Insurance Limited (CHIL), for a five-year term starting April 26, 2026. Mr. Shah, a Chartered Accountant with over 30 years of experience, has been with CHIL for 14 years and currently serves as its Chief Business Officer. The appointment has already received approval from the IRDAI and follows an internal succession plan. Under his business leadership over the last decade, CHIL's Gross Written Premium (GWP) has grown more than 30 times.
Key Highlights
Mr. Ajay Kumar Shah appointed as MD & CEO of Care Health Insurance for a 5-year term effective April 26, 2026.
IRDAI approval has been secured for the appointment, with shareholder approval pending.
Mr. Shah has 14 years of experience at CHIL and over 30 years in the insurance and financial services sectors.
CHIL's Gross Written Premium (GWP) grew over 30x during his tenure leading business verticals.
The appointment is part of an internal succession plan aimed at maintaining growth and operational stability.
💼 Action for Investors
Investors should view this as a positive move for leadership continuity in Religare's most significant subsidiary. The appointment of an internal high-performer suggests a stable growth trajectory for Care Health Insurance.
Loading analysis...
Religare Appoints Ajay Kumar Shah as MD & CEO of Care Health Insurance for 5-Year Term
Religare Enterprises has announced the appointment of Mr. Ajay Kumar Shah as the Managing Director and CEO of its material subsidiary, Care Health Insurance Limited (CHIL), effective April 26, 2026. Mr. Shah, who has been with CHIL for 14 years, previously served as the Chief Business Officer and has over 30 years of experience in the financial services sector. Under his leadership of business verticals over the last decade, CHIL's Gross Written Premium (GWP) has grown more than 30-fold. The appointment has already received approval from the IRDAI, ensuring a smooth leadership transition for this critical business unit.
Key Highlights
Mr. Ajay Kumar Shah appointed as MD & CEO of Care Health Insurance for a 5-year term starting April 26, 2026.
CHIL's Gross Written Premium (GWP) grew over 30x during his 10-year tenure leading business verticals.
The appointment has received formal approval from the IRDAI and follows an internal succession plan.
Mr. Shah is a Chartered Accountant with over 30 years of experience in Insurance and Financial Services.
💼 Action for Investors
Investors should view this as a positive development for business continuity and growth, given the appointee's significant role in CHIL's historical scaling. Monitor the subsidiary's performance as it remains a primary value driver for Religare Enterprises.
Loading analysis...
Religare to Hold EGM for Office Shift and Appointment of Executive Director with ₹9 Cr Salary
Religare Enterprises has scheduled an Extraordinary General Meeting (EGM) on May 05, 2026, to seek shareholder approval for shifting its registered office from Delhi to Haryana. A key agenda item is the appointment of Mr. Arjun Lamba as Whole Time Director for a five-year term starting April 01, 2026. The proposed remuneration for Mr. Lamba includes a fixed salary of ₹9.00 crore per annum, with potential annual hikes of up to 25%. Additionally, he will be eligible for a variable bonus of up to 50% of his fixed pay and participation in the company's ESOP plan.
Key Highlights
Extraordinary General Meeting (EGM) scheduled for May 05, 2026, via Video Conferencing.
Proposal to shift the Registered Office from the National Capital Territory of Delhi to the State of Haryana.
Appointment of Mr. Arjun Lamba as Whole Time Director (Executive Director) for a 5-year tenure until March 2031.
Proposed fixed remuneration for the new Executive Director set at ₹9.00 crore per annum.
Variable pay component capped at 50% of fixed pay, alongside eligibility for Employee Stock Option Plans (ESOPs).
💼 Action for Investors
Investors should review the proposed executive remuneration package and the rationale for the office relocation during the EGM. Monitor the voting outcomes to gauge shareholder sentiment regarding the high-value management compensation.
Loading analysis...
Religare Subsidiary Care Health Gets Stay from Bombay HC on ₹35.36 Cr GST Demand & Penalty
Religare Enterprises' material subsidiary, Care Health Insurance Limited (CHIL), has obtained a stay order from the Bombay High Court against a GST demand order. The original demand included ₹17.68 crore in GST and an equivalent penalty of ₹17.68 crore, totaling approximately ₹35.36 crore excluding interest. The dispute pertains to SEZ-related matters for the period FY 2017-18 to FY 2023-24. The stay provides temporary financial relief as the company contests what it describes as an industry-wide tax issue.
Key Highlights
Bombay High Court granted a stay on the GST order-in-original until final disposal of the writ petition.
The total financial implication involves a tax demand of ₹17.68 crore and a penalty of ₹17.68 crore.
The tax dispute covers a seven-year period from July 2017 to March 2024 regarding SEZ matters.
Religare identifies the tax demand as part of an industry-wide issue rather than a company-specific lapse.
💼 Action for Investors
Investors should monitor the final outcome of the writ petition as the stay is temporary, though it prevents immediate cash outflow. The resolution of this 'industry-wide' issue will be a significant indicator for the subsidiary's long-term tax liabilities.
Loading analysis...
Religare Appoints Arjun Lamba as Executive Director for 5 Years; New Chairperson Named
Religare Enterprises has announced a significant leadership transition, appointing Mr. Arjun Lamba as Whole Time Director (Executive Director) for a five-year term effective April 1, 2026. Mr. Lamba, who has over 23 years of experience in capital markets, was notably involved in the Burman family's acquisition efforts for Religare and Eveready. Additionally, Mr. Rajender Mohan Malla will serve as the Non-Executive Chairperson for a short interim period from April 1 to June 30, 2026. These appointments are subject to shareholder approval and signal a potential shift in strategic direction under the influence of major stakeholders.
Key Highlights
Mr. Arjun Lamba appointed as Whole Time Director for a 5-year term starting April 1, 2026
Mr. Rajender Mohan Malla appointed as Non-Executive Chairperson for a 3-month tenure ending June 30, 2026
Mr. Lamba brings 23+ years of experience and is the founder of Guardian Advisors, a SEBI-registered PMS
Appointment is significant as Mr. Lamba played a key role in the Burman family's acquisition of Religare Enterprises
The leadership changes are subject to the approval of the company's shareholders
💼 Action for Investors
Investors should monitor how this leadership change affects the ongoing corporate governance dynamics and the potential takeover bid by the Burman family. The short-term appointment of the Chairperson suggests further board restructuring may be expected by mid-2026.
Loading analysis...
Religare Subsidiary Care Health Insurance Receives Rs 140.20 Cr Income Tax Demand
Religare Enterprises' material subsidiary, Care Health Insurance Limited (CHIL), has received income tax demand orders totaling Rs 140.20 crore for the assessment years 2023-24 and 2024-25. The demand arises from disallowances related to claim provisions (IBNR/IBNER) and marketing expenses, which the company claims are industry-wide issues. CHIL expects to reduce the demand to approximately Rs 96 crore through a rectification application and intends to appeal the orders. The company notes that similar issues have been adjudicated in its favor by judicial forums in previous years.
Key Highlights
Cumulative income tax demand of Rs 140.20 crore (including interest) issued against Care Health Insurance Limited.
Demand pertains to Assessment Years 2023-24 and 2024-25 regarding disallowances of claim provisions and marketing expenses.
Company estimates the demand will be rectified down to approximately Rs 96 crore post-correction of computation errors.
CHIL plans to file an appeal, citing that IBNR/IBNER issues were previously settled in their favor by the Delhi High Court.
The tax demand, if finalized, will impact the consolidated financials of Religare Enterprises Limited.
💼 Action for Investors
Investors should monitor the outcome of the rectification and appeal process as the demand represents a significant contingent liability. While the company has a history of favorable rulings on these specific issues, the immediate demand may create short-term pressure on the stock.
Loading analysis...
Religare Enterprises Q3 FY26 Income Rises to ₹2,067.9 Cr; Care Health AUM Crosses ₹10,000 Cr
Religare Enterprises reported a consolidated total income of ₹2,067.9 crores for Q3 FY26, up from ₹1,670.2 crores in the same quarter last year. Despite revenue growth, the company posted a consolidated loss before tax of ₹103.1 crores, impacted by one-time employee benefit provisions under the new labor code. The insurance subsidiary, Care Health, remains a strong performer with retail business growing 41% and its AUM crossing the ₹10,000 crore milestone. Governance remains a focal point with the proposed induction of Burman family members and Jimeet Modi to the Board.
Key Highlights
Consolidated total income increased to ₹2,067.9 crores in Q3 FY26 vs ₹1,670.2 crores in Q3 FY25.
Care Health Insurance retail premium grew by 41% YoY, with total 9M premium reaching ₹7,906 crores.
Care Health AUM crossed ₹10,000 crores with a solvency ratio of 1.70 as of December 2025.
One-time wage code provisions of ₹13.5 crores impacted quarterly profitability in the insurance segment.
Board expansion proposed to include Dr. Anand Burman, Mohit Burman, Aditya Chand Burman, and Jimeet Modi.
💼 Action for Investors
Investors should monitor the transition in board leadership and the impact of the new management team on long-term strategy. While the consolidated loss is a concern, the robust growth and market share gains in the health insurance subsidiary provide a strong underlying valuation support.
Loading analysis...
Religare Enterprises Reports Q3 FY26 Net Loss of ₹76.5 Cr; Care Health GWP Grows to ₹7,906 Cr
Religare Enterprises Limited (REL) reported a consolidated net loss of ₹76.5 crore for Q3 FY26, compared to a loss of ₹63.2 crore in the same period last year. While total income grew by 23.8% YoY to ₹2,067.9 crore, rising expenses and higher claims in the insurance segment weighed on profitability. Care Health Insurance remains the primary growth engine, contributing ₹7,906 crore in GWP for 9M FY26 with a 22% market share in the SAHI segment. The company's NBFC arm, Religare Finvest, is now debt-free with over ₹500 crore in cash reserves following successful NPA recoveries.
Key Highlights
Consolidated Total Income increased 23.8% YoY to ₹2,067.9 crore in Q3 FY26.
Care Health Insurance GWP grew to ₹7,906 crore for 9M FY26, up from ₹6,508 crore YoY.
Consolidated Net Loss for 9M FY26 stood at ₹22.5 crore versus a profit of ₹32 crore in 9M FY25.
Care Health's AUM crossed a significant milestone, reaching ₹10,246 crore as of December 2025.
Religare Finvest (NBFC) has resolved legacy issues and maintains a cash balance of ₹500+ crore.
💼 Action for Investors
Investors should focus on the improving operational metrics of Care Health and the debt-free status of the NBFC arm, while remaining cautious about the widening consolidated losses. Monitor the combined ratio in the insurance business, which rose to 111.1% in Q3 FY26, as a key indicator of future profitability.
Loading analysis...
Religare Enterprises Announces Strategic Demerger of Financial Services; 1:1 Share Swap Ratio
Religare Enterprises (REL) has approved a demerger to separate its financial services and insurance businesses into two independent listed entities. The financial services business, including lending and broking, will be transferred to Religare Finvest Limited (RFL), while REL will retain the insurance business through Care Health Insurance. Shareholders will receive 1 share of RFL for every 1 share held in REL. The demerged undertaking contributed ₹457.29 crore (6.2%) to the consolidated turnover in FY25.
Key Highlights
Demerger of lending, broking, and investment activities into Religare Finvest Limited (RFL)
Shareholders to receive 1 fully paid-up equity share of RFL for every 1 share held in REL
Demerged business accounted for ₹457.29 crore (6.2%) of FY25 consolidated turnover
REL to remain an insurance-focused entity holding the stake in Care Health Insurance Limited
RFL to be listed on BSE and NSE with a target completion date in Q1 FY28
💼 Action for Investors
Investors should maintain their positions to benefit from the value unlocking of two distinct business platforms. Monitor the progress of regulatory approvals from the RBI and NCLT, as these are critical for the Q1 FY28 listing timeline.
Loading analysis...
Religare Enterprises Announces 1:1 Demerger of Financial Services Business into Religare Finvest
Religare Enterprises (REL) has approved a scheme to demerge its financial services, broking, and investment businesses into its subsidiary, Religare Finvest Limited (RFL). Shareholders will receive one equity share of RFL for every one share held in REL, with RFL set to be listed on both BSE and NSE. The demerged undertaking contributed INR 457.29 Crores, or 6.2% of the total consolidated turnover, in FY25. Post-demerger, REL will focus on its insurance business through Care Health Insurance, while RFL will operate as an independent lending and broking entity.
Key Highlights
Shareholders to receive 1 share of Religare Finvest for every 1 share held in Religare Enterprises.
Demerged financial services division reported a turnover of INR 457.29 Crores (6.2% of total) in FY25.
Religare Enterprises will retain its core investment and shareholding in Care Health Insurance Limited.
Religare Finvest (RFL) is expected to be listed on BSE and NSE by Q1 FY28.
The scheme involves a 100% mirror-image shareholding pattern for the new listed entity.
💼 Action for Investors
Investors should maintain their positions to benefit from the value unlocking of two distinct listed entities. However, note the long implementation timeline with listing expected only by Q1 FY28.
Loading analysis...
Religare Enterprises Reports Q3 FY26 Standalone Net Loss of ₹11.31 Crore
Religare Enterprises reported a standalone net loss of ₹1,131.19 lakhs for the quarter ended December 31, 2025, a significant increase from the ₹397.38 lakhs loss reported in the previous quarter. Total income for the quarter plummeted to ₹238.61 lakhs from ₹759.58 lakhs in Q2 FY26, largely due to a sharp reduction in 'Other Income'. Expenses rose to ₹1,381.50 lakhs, primarily driven by employee benefit costs which more than doubled to ₹848.95 lakhs. The company continues to face ongoing income tax litigations, as noted by the statutory auditors in their limited review report.
Key Highlights
Standalone net loss widened to ₹11.31 crore in Q3 FY26 compared to a loss of ₹3.97 crore in Q2 FY26.
Total income declined by 68.6% quarter-on-quarter to ₹2.39 crore.
Employee benefit expenses surged to ₹8.49 crore from ₹3.38 crore in the preceding quarter.
The company reported a negative Earnings Per Share (EPS) of ₹0.34 for the quarter.
Auditors included an 'Emphasis of Matter' regarding ongoing income tax litigations and related demands.
💼 Action for Investors
Investors should exercise caution as the standalone entity's losses are widening and operational expenses are rising. The focus should remain on the performance of its underlying subsidiaries in insurance and broking, as well as the resolution of legal and tax contingencies.
Loading analysis...
Religare Enterprises Clarifies on Care Health Insurance Demerger and Listing Rumors
Religare Enterprises Limited has issued a clarification to the stock exchanges regarding a media report suggesting a potential demerger and listing of Care Health Insurance. The company stated that there is currently no pending information or event that requires disclosure under SEBI (LODR) Regulations. While management acknowledges they evaluate strategic growth opportunities on an ongoing basis, they confirmed that the news item has no material impact at this stage. This response effectively denies any immediate or finalized plans for the rumored demerger.
Key Highlights
Exchange sought clarification on a Moneycontrol article dated February 03, 2026, regarding Care Health Insurance.
Company confirms no event currently exists that requires disclosure under SEBI Regulation 30.
Religare states there is no material impact on the company resulting from the news article.
Management maintains they evaluate strategic opportunities for growth and expansion on an ongoing basis.
The response was filed on February 03, 2026, in response to surveillance queries from BSE and NSE.
💼 Action for Investors
Investors should treat the demerger news as speculative until an official board-approved announcement is made. Monitor the stock for price volatility as the market reacts to the company's denial of immediate plans.
Loading analysis...
Religare Subsidiary Care Health Insurance Rating Upgraded to IND AA-/ Stable
India Ratings & Research (Ind-Ra) has upgraded the credit rating of Care Health Insurance Limited, a material subsidiary of Religare Enterprises. The rating has been moved to 'IND AA-' with a 'Stable' outlook as of January 29, 2026. This upgrade signifies improved financial strength and operational stability for the subsidiary, which is a key value driver for the parent company. Such a rating improvement typically enhances the subsidiary's ability to attract capital and reflects a robust solvency profile.
Key Highlights
Credit rating of material subsidiary Care Health Insurance upgraded to IND AA-.
Rating outlook assigned as 'Stable' by India Ratings & Research (Ind-Ra).
The rating action was communicated on January 29, 2026, and officially disclosed on January 30, 2026.
Care Health Insurance is a significant contributor to the consolidated performance of Religare Enterprises.
💼 Action for Investors
Investors should view this upgrade as a positive development for Religare's valuation, as its health insurance arm shows strengthening fundamentals. Maintain a positive outlook on the stock while monitoring the subsidiary's growth in the competitive health insurance market.
Loading analysis...
Religare Subsidiary Care Health Insurance Fined ₹1 Crore by IRDAI
Care Health Insurance Limited (CHIL), a material subsidiary of Religare Enterprises, has been penalized ₹1 crore by the IRDAI for various regulatory violations. The penalty follows an inspection conducted in 2021 which identified breaches in Third Party Administrator (TPA) health services and corporate governance guidelines. In addition to the monetary fine, the regulator issued warnings and advisories regarding financial statement preparation and policyholder interest protection. While the financial impact is limited, the regulatory focus on governance at a key subsidiary is noteworthy for shareholders.
Key Highlights
IRDAI imposed a ₹1 crore penalty on Care Health Insurance Limited (CHIL) for regulatory non-compliance.
Violations relate to TPA Health Services regulations and Corporate Governance guidelines identified during a 2021 inspection.
The regulator also issued formal warnings and advisories concerning financial reporting and policyholder protection.
The penalty is payable by CHIL and will be reflected in the consolidated financial statements of Religare Enterprises.
The order was received on December 15, 2025, following a review of the company's submissions.
💼 Action for Investors
Investors should monitor for any further governance-related disclosures, as repeated regulatory friction can impact the valuation of the insurance subsidiary. The immediate financial impact of ₹1 crore is negligible relative to Religare's overall scale.
Loading analysis...
Religare Allots 19,85,816 Equity Shares on Warrant Conversion
Religare Enterprises Limited has allotted 19,85,816 equity shares upon conversion of warrants. The face value of each share is ₹10, with a premium of ₹225 each. The allotment was made to promoter entities following the receipt of ₹35,00,00,070, representing 75% of the balance consideration for the warrants. Post-allotment, the issued, subscribed, and paid-up equity share capital of the company increased to ₹3,32,74,04,790, consisting of 33,27,40,479 fully paid-up equity shares.
Key Highlights
Allotment of 19,85,816 equity shares upon warrant conversion.
₹35,00,00,070 received as balance consideration for warrants.
Equity share capital increased to ₹3,32,74,04,790 post allotment.
Each share has a face value of ₹10 with a premium of ₹225.
💼 Action for Investors
Investors should note the increase in equity share capital and monitor the impact of the increased promoter holding on the company's future performance. Review the updated shareholding pattern for changes in promoter influence.